THERAPEUTIC AGENT FOR MUSCULAR DYSTROPHY
    3.
    发明公开
    THERAPEUTIC AGENT FOR MUSCULAR DYSTROPHY 审中-公开
    治疗剂,肌

    公开(公告)号:EP2641609A4

    公开(公告)日:2014-07-23

    申请号:EP11841477

    申请日:2011-11-17

    申请人: FUKUDA KEIICHI

    IPC分类号: A61K38/00 A61P21/00

    CPC分类号: A61K38/193

    摘要: The present invention provides therapeutic agents for diseases associated with skeletal muscle degeneration comprising a granulocyte colony-stimulating factor (G-CSF) as an active ingredient. The therapeutic agents of the present invention are especially effective as therapeutic agents for muscular dystrophy.

    THERAPEUTIC AGENT FOR MUSCULAR DYSTROPHY
    4.
    发明公开
    THERAPEUTIC AGENT FOR MUSCULAR DYSTROPHY 审中-公开
    治疗MITTELFÜRMUSKELDYSTROPHIE

    公开(公告)号:EP2641609A1

    公开(公告)日:2013-09-25

    申请号:EP11841477.0

    申请日:2011-11-17

    申请人: Fukuda, Keiichi

    IPC分类号: A61K38/00 A61P21/00

    CPC分类号: A61K38/193

    摘要: The present invention provides therapeutic agents for diseases associated with skeletal muscle degeneration comprising a granulocyte colony-stimulating factor (G-CSF) as an active ingredient. The therapeutic agents of the present invention are especially effective as therapeutic agents for muscular dystrophy.

    摘要翻译: 本发明提供了与骨骼肌变性相关的疾病的治疗剂,其包含粒细胞集落刺激因子(G-CSF)作为活性成分。 本发明的治疗剂作为肌营养不良症的治疗剂是特别有效的。

    REMEDY FOR ANGIOGENESIS-RELATED DISEASE COMPRISING CHONDROMODULIN-I AS THE ACTIVE INGREDIENT
    5.
    发明公开
    REMEDY FOR ANGIOGENESIS-RELATED DISEASE COMPRISING CHONDROMODULIN-I AS THE ACTIVE INGREDIENT 审中-公开
    MITTEL ZUR BEHANDLUNG VON ANGIOGENESE-BEDINGTEN ERKRANKUNGEN MIT CHONDROMODULIN-I ALS WIRKSTOFF

    公开(公告)号:EP1946765A1

    公开(公告)日:2008-07-23

    申请号:EP06810198.9

    申请日:2006-09-15

    摘要: An objective of the present invention is to analyze the function of anti-angiogenic factors in cardiac valves or such to elucidate the developmental mechanism of angiogenesis-induced diseases. A more specific objective is to provide therapeutic agents for angiogenesis-induced diseases such as valvular heart disease, and methods of efficiently screening for the therapeutic agents. The present inventors discovered that chondromodulin-I was markedly expressed in cardiac valves, and plays an important role in maintaining normal functions of the valves by preventing angiogenesis, thickening, and calcification which lead to valvular heart diseases. Chondromodulin-I proteins and substances that activate the expression or function of the proteins are expected to have therapeutic effects against angiogenesis-induced diseases.

    摘要翻译: 本发明的目的是分析心脏瓣膜中的抗血管生成因子的功能,以阐明血管生成诱发的疾病的发展机制。 更具体的目的是提供血管生成诱导的疾病如瓣膜性心脏病的治疗剂和有效筛选治疗剂的方法。 本发明人发现软骨调节蛋白-1在心脏瓣膜中显着表达,并且通过预防血管生成,增厚和钙化导致瓣膜性心脏病的维持瓣膜的正常功能起重要作用。 软骨调节蛋白-1蛋白质和激活蛋白质表达或功能的物质预期具有对血管生成诱导的疾病的治疗作用。